HC Wainwright Comments on Oculis’ Q1 Earnings (NASDAQ:OCS)

Oculis Holding AG (NASDAQ:OCS) – Research analysts at HC Wainwright upped their Q1 2025 earnings estimates for Oculis in a report released on Thursday, March 13th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.43) per share for the quarter, up from their prior estimate of ($0.50). HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.41) EPS and FY2025 earnings at ($1.63) EPS.

Oculis (NASDAQ:OCS) last announced its earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%.

Several other equities analysts also recently weighed in on the company. Chardan Capital restated a “buy” rating and issued a $28.00 target price on shares of Oculis in a research report on Thursday, March 13th. Robert W. Baird lifted their target price on shares of Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research note on Thursday, March 13th.

Oculis Stock Performance

NASDAQ:OCS opened at $18.83 on Monday. The company has a fifty day moving average of $20.94 and a two-hundred day moving average of $17.05. Oculis has a fifty-two week low of $10.55 and a fifty-two week high of $23.08. The stock has a market capitalization of $822.16 million, a PE ratio of -9.76 and a beta of 0.01. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02.

Hedge Funds Weigh In On Oculis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OCS. abrdn plc increased its position in Oculis by 23.0% during the fourth quarter. abrdn plc now owns 1,009,424 shares of the company’s stock worth $17,150,000 after purchasing an additional 188,871 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after buying an additional 1,800 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Oculis during the 4th quarter worth approximately $225,000. Bellevue Group AG purchased a new stake in shares of Oculis during the 4th quarter valued at approximately $170,000. Finally, Bank of America Corp DE lifted its holdings in Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after acquiring an additional 10,667 shares during the last quarter. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.